SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci. 1994; 19: 459463.
  • 2
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2: 127137.
  • 3
    Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther. 2004; 102: 3746.
  • 4
    Wells A. EGF receptor. Int J Biochem Cell Biol. 1999; 31: 637643.
  • 5
    Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37( Suppl 4): S3S8.
  • 6
    Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183232.
  • 7
    Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001; 8: 8396.
  • 8
    Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2139.
  • 9
    Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 3–4: 14971500.
  • 10
    Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol. 1995; 69: 43904398.
  • 11
    Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001; 13: 506513.
  • 12
    Hadari YR, Doody JF, Wang Y, et al. The IgG1 monoclonal antibody cetuximab induces degradation of the epidermal growth factor receptor. Presented at the annual meeting of the American Society for Clinical Oncology, 2004. Abstract 234.
  • 13
    Kang X, Patel D, Shi J, Hicklin D. Anti-EGFR monoclonal antibody cetuximab binds the EGFR variant III receptor and internalizes phosphorylated receptor on the cell surface (abstract). Eur J Cancer. 2002; 38: 149.
  • 14
    Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000; 18: 904914.
  • 15
    Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999; 59: 19351940.
  • 16
    Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996; 56: 36663669.
  • 17
    Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999; 5: 257265.
  • 18
    Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc). 2003; 39( Suppl C): 116.
  • 19
    Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (cetuximab) suppresses DNA-PK activity. Radiother Oncol. 2005; 76: 157161.
  • 20
    Khazaeli MB, LoBuglio AF, Falcey JW, Paulter VJ, Fetzer KM, Waksal HW. Low immunogenicity of a chimeric monoclonal antibody (MoAb), IMC-C225, used to treat epidermal growth factor recepto-positive tumors. Presented at the annual meeting of the American Society for Clinical Oncology, 2002. Abstract 808.
  • 21
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med. 2004; 351: 337345.
  • 22
    Saltz LB, Meropol NJ, Loehrer PJSr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 12011208.
  • 23
    Bonner JA, Harari PM, Giralt J, et al. Cetuximab improves locoregional control and survival of locoregionally advanced head and neck cancer: independent review of mature data with a median follow-up of 45 months. Presented at the AACR-NCI-EORTC meeting, November 14–18, 2005. Abstract B106.
  • 24
    Bonner J, Harari P, Giralt J, et al. Improved preservation of larynx with addition of cetuximab to radiation for cancers of the larynx and hypopharynx. Presented at the annual meeting of the American Society for Clinical Oncology, May 13–17, 2005. Abstract 5533.
  • 25
    Kim ES, Mauer AM, Tran HT, et al. A Phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: final report. Presented at the annual meeting of the American Society for Clinical Oncology, 2003. Abstract 2581.
  • 26
    Humblet Y, Vega-Villegas E, Mesia R, et al. Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). Presented at the annual meeting of the American Society for Clinical Oncology, 2004. Abstract 5513.
  • 27
    Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999; 14: 451463.
  • 28
    Pippas AW, Lenz H-J, Mayer RJ, Mirtsching B, et al. Analysis of EGFR status in metastatic colorectal cancer patients treated with cetuximab monotherapy. Presented at the annual meeting of the American Society for Clinical Oncology, 2005. Abstract 3595.
  • 29
    Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005; 23: 18031810.
  • 30
    Bishop PC, Myers T, Robey R, et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene. 2002; 21: 119127.
  • 31
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, version 2. Colon cancer. Jenkintown: National Comprehensive Cancer Network, 2006.
  • 32
    Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004; 58: 984990.
  • 33
    Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001; 38: 1723.
  • 34
    Yang XD, Jia XC, Corvalan J, et al. Therapeutic potential of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer treatment. Presented at the annual meeting of the American Society for Clinical Oncology, 2000. Abstract 183.
  • 35
    Schwartz G, Dutcher JP, Vogelzang NJ, et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC). Proc Am Soc Clin Oncol. 2002; 21: 24a. Abstract 91.
  • 36
    Meropol NJ, Berlin J, Hecht JR, et al. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 2003; 22: 256. Abstract 1026.
  • 37
    Wallace PK, Romet-Lemonne JL, Chokri M, Kasper LH, Fanger MW, Fadul CE. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer Immunol Immunother. 2000; 49: 493503.
  • 38
    Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 15271537.
  • 39
    Kelly K, Gaspar LE, Chansky K, Albain KS, Crowley J, Gandara DR. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing Phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc Am Assoc Clin Oncol. 2005;23:1058.
  • 40
    US Food and Drug Administration. FDA public health advisory: new labeling and distribution program for gefitinib (Iressa). Washington, DC: US Food and Drug Administration, 2005.
  • 41
    Baselga J, Averbuch SD. ZD1839 (‘Iressa’) as an anticancer agent. Drugs. 2000; 60( Suppl)1: 3340.
  • 42
    Ciardiello F, Caputo R, Bianco R, Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000; 6: 20532063.
  • 43
    Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2000; 6: 48854892.
  • 44
    Blackledge G, Averbuch S. Gefitinib (‘Iressa’; ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004; 90: 566572.
  • 45
    Inomata S, Takahashi H, Nagata M, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs. 2004; 15: 461467.
  • 46
    Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003; 21: 19801987.
  • 47
    Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005; 11: 84188424.
  • 48
    Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003; 21: 22372246.
  • 49
    Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 21492158.
  • 50
    Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004; 22: 133142.
  • 51
    Daneshmand M, Parolin DA, Hirte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients. Clin Cancer Res. 2003; 9: 24572464.
  • 52
    Dorligschaw O, Kegel T, Jordon K, Harba A, Grothey A, Schmoll H-J. ZD 1839 (Iressa)-based treatment as last-line therapy in patients with advanced colorectal cancer (ACRC). Presented at the annual meeting of the American Society for Clinical Oncology, 2003. Abstract 1494.
  • 53
    Drucker B, Bacik J, Ginsberg M, et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs. 2003; 21: 341345.
  • 54
    Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial—INTACT 2. J Clin Oncol. 2004; 22: 785794.
  • 55
    Bailey LR, Kris M, Wolf M, et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa’; ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res. 2003; 44: 1362. Abstract LB-170.
  • 56
    Lynch TJ, Bell D, Haber D, et al. Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy, or chemotherapy and gefitinib in IDEAL and INTACT clinical trials. Program and abstracts of the 41st annual meeting of the American Society of Clinical Oncology, Orlando, Florida, May 13–17, 2005. Abstract 7006.
  • 57
    Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352: 786792.
  • 58
    Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005; 2: e73.
  • 59
    Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA. 2005; 102: 76657670.
  • 60
    Moyer JD, Barbacci EG, Iwata KK, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997; 57: 48384848.
  • 61
    Iwata K, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Presented at the annual meeting of the American Society of Clinical Oncology, 2002. Abstract 79.
  • 62
    Hidalgo M. Erlotinib: preclinical investigations. Oncology (Huntingt). 2003; 17: 1116.
  • 63
    Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther. 1999; 291: 739748.
  • 64
    Hidalgo M, Siu LL, Nemunaitis J. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001; 19: 32673279.
  • 65
    Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004; 22: 7785.
  • 66
    Perez-Soler R, Chachoua A, Huberman M, et al. A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Presented at the annual meeting of the American Society of Clinical Oncology, 2001. Abstract 1235.
  • 67
    Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123132.
  • 68
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Presented at the annual meeting of the American Society of Clinical Oncology, 2005. Abstract 1.
  • 69
    Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a Phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). Presented at the annual meeting of the American Society of Clinical Oncology, 2004. Abstract 7010.
  • 70
    Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23: 58925899.
  • 71
    Nyati MK, Maheshwari D, Hanasoge S, et al. Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res. 2004; 10: 691700.
  • 72
    Zinner RG, Donato NJ, Nemunaitis JJ, et al. Biomarker modulation in tumor an skin biopsy samples from patients with solid tumors following treatment with the pan-erbB tyrosine kinase inhibitor, CI-1033. Presented at the annual meeting of the American Society of Clinical Oncology, 2002. Abstract 58.
  • 73
    Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 2002; 21: 24072417.
  • 74
    Garrison MA, Tolcher A, McCreery H, et al. A Phase I and pharmacokinetic study of CI-1033, a pan-erbB tyrosine kinase inhibitor, given orally on Days 1, 8, and 15 every 28 days to patients with solid tumors. Presented at the annual meeting of the American Society of Clinical Oncology, 2001. Abstract 289.
  • 75
    Shin DM, Nemunaitis J, Zinner RG, et al. A Phase I clinical and biomarker study of CI-1033, a novel pan-ErbB tyrosine kinase inhibitor in patients with solid tumors. Presented at the annual meeting of the American Society of Clinical Oncology, 2001. Abstract 324.
  • 76
    Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differently inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cells and normal human keratinocytes. Mol Cancer Ther. 2004; 3: 2127.
  • 77
    Hidalgo M, Erlichman C, Rowinsky EK, et al. Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. Presented at the annual meeting of the American Society of Clinical Oncology, 2000. Abstract 65.
  • 78
    Morgan JA, Bukowski RM, Xiong H, et al. Preliminary report of a phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), given in combination with gemcitabine to patients with advanced pancreatic cancer. Presented at the annual meeting of the American Society of Clinical Oncology, 2003. Abstract 788.
  • 79
    Gomez HL, Chavez MA, Doval DC, et al. A Phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. Presented at the annual meeting of the American Society of Clinical Oncology, 2005. Abstract 3046.
  • 80
    Ross HJ, Blumenschein GR, Dowlati A, et al. Preliminary safety results of a Phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer. Presented at the annual meeting of the American Society for Clinical Oncology, 2005.Abstract 7099.
  • 81
    Storniolo A, Burris H, Pegram M, et al. A Phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. Presented at the annual meeting of the American Society for Clinical Oncology, 2005. Abstract 559.
  • 82
    Miknis G, Wallace E, Lyssikatos J, et al. ARRY-334543, a potent, orally active small molecule inhibitor of EGFR and ErbB-2. Presented at the 96th annual meeting of the AACR, Anaheim, California, April 16–20, 2005. Abstract 3399.
  • 83
    Baselga J. New technologies in epidermal growth factor receptor-targeted cancer therapy. Signal. 2000; 1: 1221.
  • 84
    Fallon KB, Havlioglu N, Hamilton LH, Cheng TP, Carroll SL. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line. J Neuro-Oncol. 2004; 60: 273284.
  • 85
    Pollack A. ImClone's cancer drug is back, and U.S. approval is expected. New York Times. Section C, Column 3; February 11, 2004.
  • 86
    Chabner BA. The miracle of Iressa. Oncologist. 2004; 9: 245246.
  • 87
    Saltz LB, Lenz H, Hochster H, et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at the annual meeting of the American Society for Clinical Oncology, 2005. Abstract 3508.
  • 88
    Donelan K, DesRoches CM, Schoen C. Inadequate health insurance: costs and consequences. Med Gen Med. 2000; 2: E37.
  • 89
    Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002; 40: IV17.
  • 90
    Halbert RJ, Zaher C, Wade S, Malin J, Lawless GD, Dubois RW. Outpatient cancer drug costs: changes, drivers, and the future. Cancer. 2002; 94: 11421150.
  • 91
    Koperna T, Semmler D. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. Hepatogastroenterology. 2003; 50: 19031909.
  • 92
    Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer. 2003; 3: 912920.
  • 93
    Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005; 23: 72657277.
  • 94
    Zhang W, Yun J, Press OA, et al. Association of cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225). Presented at the annual meeting of the American Society for Clinical Oncology, 2004. Abstract 3518.
  • 95
    ImClone Systems Inc., Bristol-Myers Squibb Company. Erbitux™ (cetuximab). US prescribing information. Princeton: ImClone Systems Inc., 2004.
  • 96
    Hecht JR, Patnaik A, Malik I, et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): an updated analysis. Presented at the annual meeting of the American Society for Clinical Oncology, 2004. Abstract 3511.
  • 97
    Crombet T, Torres O, Rodriguez V, et al. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma. 2001; 20: 131136.
  • 98
    Crombet-Ramos T, Figueredo J, Catala M, et al. Treatment of high-grade astrocytic tumors with the humanized anti-EGF-R antibody h-R3 and radiotherapy. Presented at the annual meeting of the American Society for Clinical Oncology, 2005. Abstract 2554.
  • 99
    Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 175184.
  • 100
    Tabernero J, Rojo F, Jimenez E, et al. A Phase I PK and serial tumor and skin pharmacodynamic (PD) study of weekly (q1w), every 2-week (q2w) or every 3-week (q3w) 1-hour (h) infusion EMD72000, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients (pt) with advanced tumors. Presented at the annual meeting of the American Society for Clinical Oncology, 2003. Abstract 770.
  • 101
    Salazar R, Tabernero J, Rojo F, et al. Dose-dependent inhibition of the EGFR and signalling pathways with the anti-EGFR monoclonal antibody (Mab) EMD 72000 administered every three weeks (q3w). A Phase I pharmacokinetic/pharmacodynamic (PK/PD) study to define the optimal biological dose (OBD). Presented at the annual meeting of the American Society for Clinical Oncology, 2004. Abstract 2002.
  • 102
    Curnow RT. Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother. 1997; 45: 210215.
  • 103
    Johns TG, Stockert E, Ritter G, et al. Novel monoclonal antibody specific for the de2–7 epidermal growth factor receptor (EGFR) that also recognizes the EGFR expressed in cells containing amplification of the EGFR gene. Int J Cancer. 2002; 98: 398408.
  • 104
    Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001; 61: 53495354.
  • 105
    AstraZeneca. Iressa (gefitinib) package insert. Wilmington: AstraZeneca, 2004.
  • 106
    OSI Pharmaceuticals. Tarceva™ (erlotinib) [package insert]. Melville: OSI Pharmaceuticals, 2004.
  • 107
    Tejpar S, Van Cutsem E, Gamelin E, et al. Phase 1/2a study of EKB-569,an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). Presented at the annual meeting of the American Society for Clinical Oncology, 2004. Abstract 3579.
  • 108
    Casado E, Folprecht G, Paz-Ares L, et al. A Phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). Presented at the annual meeting of the American Society for Clinical Oncology, 2004. Abstract 3543.
  • 109
    Cole GWJr., Alleva AM, Reddy RM, et al. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. J Thorac Cardiovasc Surg. 2005; 129: 10101017.
  • 110
    Garland LL, Pegram M, Song S, et al. Phase I study of BMS-599626, an oral pan-HER tyrosine kinase inhibitor, in patients with advanced solid tumors. Proceedings of the annual meeting of the American Society for Clinical Oncology, 2005. J Clin Oncol. 2005; 23( Suppl): 16S. Abstract 3152.
  • 111
    Hoekstra R, Dumez H, van Oosterom AT, et al. A Phase I and pharmacological study of PK1166, and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Presented at the annual meeting of the American Society for Clinical Oncology, 2002. Abstract 340.
  • 112
    Park YW, Younes MN, Jasser SA, et al. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice. Clin Cancer Res. 2005; 11: 19631973.
  • 113
    Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res. 2005; 65: 37163725.
  • 114
    Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003; 4: 397406.